The company said its two preferred uses of cash are share buybacks to return cash to shareholders and targeted M&A, according to TheFlyonTheWall. Boston Scientific said it will always be opportunistic with M&A and will always look to return cash to shareholders.
Furthermore, the company said it is focused on operating income and EPS growth and it feels "comfortable" with tax rate guidance.
Must Read: Warren Buffett's 25 Favorite StocksSTOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.
The stock was down 2.32% to $12.62 at 10:40 a.m. STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts